Eric Loumeau Sells 10,000 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric Loumeau sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $51.00, for a total transaction of $510,000.00. Following the transaction, the insider directly owned 8,947 shares in the company, valued at approximately $456,297. The trade was a 52.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

AnaptysBio Stock Down 0.0%

ANAB stock opened at $50.03 on Thursday. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -17.74 and a beta of 0.29. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $51.43. The firm has a 50 day moving average of $39.83 and a two-hundred day moving average of $29.55.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. On average, research analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has authorized a stock buyback plan on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On AnaptysBio

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC raised its stake in AnaptysBio by 433.3% during the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock valued at $86,139,000 after purchasing an additional 3,764,720 shares during the last quarter. Palo Alto Investors LP increased its holdings in shares of AnaptysBio by 20.9% during the 1st quarter. Palo Alto Investors LP now owns 1,020,713 shares of the biotechnology company’s stock worth $18,975,000 after purchasing an additional 176,742 shares during the period. Assenagon Asset Management S.A. raised its position in shares of AnaptysBio by 4,852.7% during the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after buying an additional 822,975 shares during the last quarter. Woodline Partners LP raised its position in shares of AnaptysBio by 63.1% during the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after buying an additional 305,950 shares during the last quarter. Finally, 683 Capital Management LLC lifted its stake in shares of AnaptysBio by 155.6% in the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $11,100,000 after buying an additional 304,373 shares during the period.

Analysts Set New Price Targets

ANAB has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. Wall Street Zen upgraded AnaptysBio from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Wells Fargo & Company lifted their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Wedbush reaffirmed an “outperform” rating and set a $50.00 price objective on shares of AnaptysBio in a report on Monday, November 24th. Finally, Truist Financial lifted their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.40.

AnaptysBio News Summary

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Recent fundamentals and capital return: AnaptysBio reported a sizable earnings and revenue beat in early November (EPS $0.52 vs. est. -$1.06; revenue $76.3M vs. est. $15.8M) and in late November the board authorized a $100M share buyback — both are bullish signs for valuation and shareholder return. MarketBeat ANAB News
• Neutral Sentiment: Analyst consensus is mildly constructive: the MarketBeat summary shows a “Moderate Buy” consensus and a mean target near $55 — mixed price targets and ratings (Buy/Outperform/Hold) leave room for upside but reflect differing views on pipeline execution. MarketBeat ANAB News
• Neutral Sentiment: Short interest data published for December is effectively zero (0 shares / 0.0 days) — the print appears anomalous and offers little signal about short pressure today.
• Negative Sentiment: Multiple insider sales this week increased perceived supply and likely weighed on sentiment: CFO Dennis Mulroy sold 10,000 shares at ~$50 (filed with the SEC), director J. Anthony Ware sold 3,900 shares at ~$49.58 (SEC filing), Eric J. Loumeau sold 10,000 shares at $51, and Paul F. Lizzul sold 1,500 shares at $50 (insider trades reported). These transactions reduced several insiders’ ownership materially and are commonly read by investors as a near‑term negative catalyst. Mulroy Form 4 Loumeau Form 4 Ware Form 4 Lizzul InsiderTrades

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.